

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 10-Q**

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the quarterly period ended March 31, 2025**

**or**

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from \_\_\_\_\_ to \_\_\_\_\_**

**Commission File Number: 1-10864**

**UnitedHealth Group Incorporated**  
**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction of**  
**incorporation or organization)**

**41-1321939**  
**(I.R.S. Employer**  
**Identification No.)**

**1 Health Drive**  
**Eden Prairie, Minnesota**  
**(Address of principal executive offices)**

**55344**  
**(Zip Code)**

**655 New York Avenue NW**  
**Washington, DC**  
**(Address of principal executive offices)**

**20001**  
**(Zip Code)**

**(800) 328-5979**

**(Registrant's telephone number, including area code)**

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$.01 par value	UNH	New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act

Large accelerated filer	<input checked="" type="checkbox"/>	Accelerated filer	<input type="checkbox"/>	Non-accelerated filer	<input type="checkbox"/>
Smaller reporting company	<input type="checkbox"/>			Emerging growth company	<input type="checkbox"/>

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of April 30, 2025, there were 907,140,441 shares of the registrant's Common Stock, \$.01 par value per share, issued and outstanding.

# UNITEDHEALTH GROUP

## Table of Contents

	<u>Page</u>
Part I. Financial Information	
Item 1. Financial Statements (unaudited) .....	1
Condensed Consolidated Balance Sheets as of March 31, 2025 and December 31, 2024 .....	1
Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2025 and 2024 ...	2
Condensed Consolidated Statements of Comprehensive Income for the Three Months Ended March 31, 2025 and 2024 .....	3
Condensed Consolidated Statements of Changes in Equity for the Three Months Ended March 31, 2025 and 2024 .....	4
Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2025 and 2024 ...	5
Notes to the Condensed Consolidated Financial Statements .....	6
1. Basis of Presentation .....	6
2. Investments .....	7
3. Fair Value .....	9
4. Medical Costs Payable .....	10
5. Short-Term Borrowings and Long-Term Debt .....	10
6. Commitments and Contingencies .....	11
7. Held for Sale .....	12
8. Segment Financial Information .....	13
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations .....	14
Item 3. Quantitative and Qualitative Disclosures About Market Risk .....	21
Item 4. Controls and Procedures .....	22
Part II. Other Information	
Item 1. Legal Proceedings .....	22
Item 1A. Risk Factors .....	22
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds .....	22
Item 5. Other Information .....	23
Item 6. Exhibits .....	23
Signatures .....	24

# PART I

## ITEM 1. FINANCIAL STATEMENTS

### UnitedHealth Group Condensed Consolidated Balance Sheets (Unaudited)

(in millions, except per share data)	March 31, 2025	December 31, 2024
<b>Assets</b>		
Current assets:		
Cash and cash equivalents .....	\$ 30,717	\$ 25,312
Short-term investments .....	3,574	3,801
Accounts receivable, net .....	26,936	22,365
Other current receivables, net .....	26,022	26,089
Prepaid expenses and other current assets .....	9,036	8,212
Total current assets .....	96,285	85,779
Long-term investments .....	51,863	52,354
Property, equipment and capitalized software, net .....	10,734	10,553
Goodwill .....	107,566	106,734
Other intangible assets, net .....	22,947	23,268
Other assets .....	20,395	19,590
<b>Total assets</b> .....	<b>\$ 309,790</b>	<b>\$ 298,278</b>
<b>Liabilities, redeemable noncontrolling interests and equity</b>		
Current liabilities:		
Medical costs payable .....	\$ 37,136	\$ 34,224
Accounts payable and accrued liabilities .....	33,566	34,337
Short-term borrowings and current maturities of long-term debt .....	9,986	4,545
Unearned revenues .....	3,296	3,317
Other current liabilities .....	29,487	27,346
Total current liabilities .....	113,471	103,769
Long-term debt, less current maturities .....	71,285	72,359
Deferred income taxes .....	3,902	3,620
Other liabilities .....	15,963	15,939
Total liabilities .....	204,621	195,687
Commitments and contingencies (Note 6)		
Redeemable noncontrolling interests .....	4,358	4,323
Equity:		
Preferred stock, \$0.001 par value - 10 shares authorized; no shares issued or outstanding .....	—	—
Common stock, \$0.01 par value - 3,000 shares authorized; 910 and 915 issued and outstanding .....	9	9
Retained earnings .....	97,934	96,036
Accumulated other comprehensive loss .....	(2,905)	(3,387)
Nonredeemable noncontrolling interests .....	5,773	5,610
Total equity .....	100,811	98,268
<b>Total liabilities, redeemable noncontrolling interests and equity</b> .....	<b>\$ 309,790</b>	<b>\$ 298,278</b>

See Notes to the Condensed Consolidated Financial Statements

**UnitedHealth Group**  
**Condensed Consolidated Statements of Operations**  
**(Unaudited)**

(in millions, except per share data)	Three Months Ended March 31,	
	2025	2024
<b>Revenues:</b>		
Premiums .....	\$ 86,534	\$ 77,988
Products .....	13,036	11,909
Services .....	8,972	8,888
Investment and other income .....	1,033	1,011
Total revenues .....	109,575	99,796
<b>Operating costs:</b>		
Medical costs .....	73,411	65,735
Operating costs .....	13,594	14,077
Cost of products sold .....	12,390	11,056
Depreciation and amortization .....	1,061	997
Total operating costs .....	100,456	91,865
<b>Earnings from operations</b> .....	9,119	7,931
Interest expense .....	(998)	(844)
Loss on sale of subsidiary and subsidiaries held for sale .....	(15)	(7,086)
<b>Earnings before income taxes</b> .....	8,106	1
Provision for income taxes .....	(1,632)	(1,222)
<b>Net earnings (loss)</b> .....	6,474	(1,221)
Earnings attributable to noncontrolling interests .....	(182)	(188)
<b>Net earnings (loss) attributable to UnitedHealth Group common shareholders</b> .....	<u>\$ 6,292</u>	<u>\$ (1,409)</u>
<b>Earnings (loss) per share attributable to UnitedHealth Group common shareholders:</b> .....		
Basic .....	<u>\$ 6.90</u>	<u>\$ (1.53)</u>
Diluted .....	<u>\$ 6.85</u>	<u>\$ (1.53)</u>
<b>Basic weighted-average number of common shares outstanding</b> .....	912	922
<b>Dilutive effect of common share equivalents</b> .....	6	—
<b>Diluted weighted-average number of common shares outstanding</b> .....	<u>918</u>	<u>922</u>
Anti-dilutive shares excluded from the calculation of dilutive effect of common share equivalents .....	6	15

See Notes to the Condensed Consolidated Financial Statements

**UnitedHealth Group**  
**Condensed Consolidated Statements of Comprehensive Income**  
**(Unaudited)**

(in millions)	Three Months Ended March 31,	
	2025	2024
<b>Net earnings (loss)</b> .....	\$ 6,474	\$ (1,221)
Other comprehensive income:		
Gross unrealized gains (losses) on investment securities during the period .....	521	(290)
Income tax effect .....	(119)	68
Total unrealized gains (losses), net of tax .....	402	(222)
Gross reclassification adjustment for net realized gains included in net earnings .....	(10)	(32)
Income tax effect .....	2	7
Total reclassification adjustment, net of tax .....	(8)	(25)
Foreign currency translation gains (losses) .....	88	(293)
Reclassification adjustment for translation losses included in net earnings (loss) .....	—	4,128
Total foreign currency translation gains .....	88	3,835
Other comprehensive income .....	482	3,588
Comprehensive income .....	6,956	2,367
Comprehensive income attributable to noncontrolling interests .....	(182)	(188)
<b>Comprehensive income attributable to UnitedHealth Group common shareholders</b> .....	<u>\$ 6,774</u>	<u>\$ 2,179</u>

See Notes to the Condensed Consolidated Financial Statements

**UnitedHealth Group**  
**Condensed Consolidated Statements of Changes in Equity**  
**(Unaudited)**

Three months ended March 31, (in millions)	Common Stock		Additional Paid-In Capital	Retained Earnings	Accumulated Other Comprehensive Loss		Nonredeemable Noncontrolling Interests	Total Equity
	Shares	Amount			Net Unrealized (Losses) Gains on Investments	Foreign Currency Translation (Losses) Gains		
Balance at January 1, 2025 .....	915	\$ 9	\$ —	\$ 96,036	\$ (2,226)	\$ (1,161)	\$ 5,610	\$ 98,268
Net earnings .....				6,292			148	6,440
Other comprehensive income .....					394	88		482
Issuances of common stock, and related tax effects .....	1	—	183					183
Share-based compensation .....			362					362
Common share repurchases .....	(6)	—	(540)	(2,482)				(3,022)
Cash dividends paid on common shares (\$2.10 per share) .....				(1,912)				(1,912)
Redeemable noncontrolling interests fair value and other adjustments .....			(5)					(5)
Acquisition and other adjustments of nonredeemable noncontrolling interests .....							194	194
Distribution to nonredeemable noncontrolling interests .....							(179)	(179)
Balance at March 31, 2025 .....	<u>910</u>	<u>9</u>	<u>—</u>	<u>97,934</u>	<u>(1,832)</u>	<u>(1,073)</u>	<u>5,773</u>	<u>100,811</u>
Balance at January 1, 2024 .....	924	\$ 9	\$ —	\$ 95,774	\$ (1,971)	\$ (5,056)	\$ 5,665	\$ 94,421
Net (loss) earnings .....				(1,409)			149	(1,260)
Other comprehensive (loss) income .....					(247)	3,835		3,588
Issuances of common stock, and related tax effects .....	2	—	242					242
Share-based compensation .....			352					352
Common share repurchases .....	(6)	—	(574)	(2,518)				(3,092)
Cash dividends paid on common shares (\$1.88 per share) .....				(1,729)				(1,729)
Redeemable noncontrolling interests fair value and other adjustments .....			(20)					(20)
Acquisition and other adjustments of nonredeemable noncontrolling interests .....							19	19
Distribution to nonredeemable noncontrolling interests .....							(151)	(151)
Balance at March 31, 2024 .....	<u>920</u>	<u>\$ 9</u>	<u>\$ —</u>	<u>\$ 90,118</u>	<u>\$ (2,218)</u>	<u>\$ (1,221)</u>	<u>\$ 5,682</u>	<u>\$ 92,370</u>

See Notes to the Condensed Consolidated Financial Statements

**UnitedHealth Group**  
**Condensed Consolidated Statements of Cash Flows**  
**(Unaudited)**

(in millions)	Three Months Ended March 31,	
	2025	2024
<b>Operating activities</b>		
Net earnings (loss) .....	\$ 6,474	\$ (1,221)
Noncash items:		
Depreciation and amortization .....	1,061	997
Deferred income taxes .....	64	(27)
Share-based compensation .....	375	372
Loss on sale of subsidiary and subsidiaries held for sale .....	15	7,086
Other, net .....	97	179
Net change in other operating items, net of effects from acquisitions and dispositions:		
Accounts receivable .....	(4,462)	(6,162)
Other assets .....	(544)	(1,927)
Medical costs payable .....	2,993	2,069
Accounts payable and other liabilities .....	(607)	(231)
Unearned revenues .....	(10)	9
Cash flows from operating activities .....	<u>5,456</u>	<u>1,144</u>
<b>Investing activities</b>		
Purchases of investments .....	(4,135)	(4,798)
Sales of investments .....	3,185	2,976
Maturities of investments .....	2,167	2,314
Cash paid for acquisitions and other transactions, net of cash assumed .....	(702)	(3,006)
Purchases of property, equipment and capitalized software .....	(898)	(743)
Loans to care providers - cyberattack .....	—	(2,164)
Repayments of care provider loans - cyberattack .....	891	—
Other, net .....	(582)	(919)
Cash flows used for investing activities .....	<u>(74)</u>	<u>(6,340)</u>
<b>Financing activities</b>		
Common share repurchases .....	(3,000)	(3,072)
Cash dividends paid .....	(1,912)	(1,729)
Proceeds from common stock issuances .....	360	486
Repayments of long-term debt .....	—	(750)
Proceeds from short-term borrowings, net .....	3,911	6,189
Proceeds from issuance of long-term debt .....	—	5,925
Customer funds administered .....	1,245	1,745
Other, net .....	(505)	(563)
Cash flows from financing activities .....	<u>99</u>	<u>8,231</u>
Effect of exchange rate changes on cash and cash equivalents .....	15	(48)
<b>Increase in cash and cash equivalents, including cash within businesses held for sale .....</b>	<b>5,496</b>	<b>2,987</b>
Less: net increase in cash within businesses held for sale .....	(91)	—
Net increase in cash and cash equivalents .....	<u>5,405</u>	<u>2,987</u>
<b>Cash and cash equivalents, beginning of period .....</b>	<b>25,312</b>	<b>25,427</b>
<b>Cash and cash equivalents, end of period .....</b>	<b><u>\$ 30,717</u></b>	<b><u>\$ 28,414</u></b>

See Notes to the Condensed Consolidated Financial Statements

**UnitedHealth Group**  
**Notes to the Condensed Consolidated Financial Statements**  
**(Unaudited)**

**1. Basis of Presentation**

UnitedHealth Group Incorporated (individually and together with its subsidiaries, “UnitedHealth Group” and the “Company”) is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone. The Company’s two distinct, yet complementary businesses — Optum and UnitedHealthcare — are working to help build a modern, high-performing health system through improved access, affordability, outcomes and experiences for the individuals and organizations the Company is privileged to serve.

The Company has prepared the Condensed Consolidated Financial Statements according to U.S. Generally Accepted Accounting Principles (GAAP) and has included the accounts of UnitedHealth Group and its subsidiaries. The year-end condensed consolidated balance sheet was derived from audited financial statements, but does not include all disclosures required by GAAP. In accordance with the rules and regulations of the U.S. Securities and Exchange Commission (SEC), the Company has omitted certain footnote disclosures that would substantially duplicate the disclosures contained in its annual audited Consolidated Financial Statements. Therefore, these Condensed Consolidated Financial Statements should be read together with the Consolidated Financial Statements and the Notes included in Part II, Item 8, “Financial Statements and Supplementary Data” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 as filed with the SEC (2024 10-K). The accompanying Condensed Consolidated Financial Statements include all normal recurring adjustments necessary to present the interim financial statements fairly.

***Use of Estimates***

These Condensed Consolidated Financial Statements include certain amounts based on the Company’s best estimates and judgments. The Company’s most significant estimates relate to estimates and judgments for medical costs payable and goodwill. Certain of these estimates require the application of complex assumptions and judgments, often because they involve matters that are inherently uncertain and will likely change in subsequent periods. The impact of any change in estimates is included in earnings in the period in which the estimate is adjusted.

***Revenues - Products and Services***

As of March 31, 2025 and December 31, 2024, accounts receivable related to products and services were \$11.7 billion and \$9.9 billion, respectively. As of March 31, 2025, revenue expected to be recognized in any future year related to remaining performance obligations, excluding revenue pertaining to contracts having an original expected duration of one year or less, contracts where revenue is recognized as invoiced and contracts with variable consideration related to undelivered performance obligations, was \$12.4 billion, of which approximately half is expected to be recognized in the next three years.



## 2. Investments

A summary of debt securities by major security type is as follows:

(in millions)	Amortized Cost	Gross Unrealized Gains	Gross Unrealized Losses	Fair Value
<b>March 31, 2025</b>				
Debt securities - available-for-sale:				
U.S. government and agency obligations .....	\$ 4,276	\$ 1	\$ (212)	\$ 4,065
State and municipal obligations .....	7,110	4	(367)	6,747
Corporate obligations .....	24,097	65	(924)	23,238
U.S. agency mortgage-backed securities .....	10,410	5	(812)	9,603
Non-U.S. agency mortgage-backed securities .....	2,939	3	(148)	2,794
Total debt securities - available-for-sale .....	48,832	78	(2,463)	46,447
Debt securities - held-to-maturity:				
U.S. government and agency obligations .....	447	1	(1)	447
State and municipal obligations .....	27	—	(3)	24
Corporate obligations .....	18	—	—	18
Total debt securities - held-to-maturity .....	492	1	(4)	489
Total debt securities .....	<u>\$ 49,324</u>	<u>\$ 79</u>	<u>\$ (2,467)</u>	<u>\$ 46,936</u>
<b>December 31, 2024</b>				
Debt securities - available-for-sale:				
U.S. government and agency obligations .....	\$ 4,600	\$ 1	\$ (274)	\$ 4,327
State and municipal obligations .....	7,357	2	(375)	6,984
Corporate obligations .....	24,391	56	(1,140)	23,307
U.S. agency mortgage-backed securities .....	10,577	1	(994)	9,584
Non-U.S. agency mortgage-backed securities .....	2,890	2	(175)	2,717
Total debt securities - available-for-sale .....	49,815	62	(2,958)	46,919
Debt securities - held-to-maturity:				
U.S. government and agency obligations .....	444	—	(2)	442
State and municipal obligations .....	28	—	(2)	26
Corporate obligations .....	40	—	—	40
Total debt securities - held-to-maturity .....	512	—	(4)	508
Total debt securities .....	<u>\$ 50,327</u>	<u>\$ 62</u>	<u>\$ (2,962)</u>	<u>\$ 47,427</u>

The Company held \$5.1 billion and \$4.9 billion of equity securities as of March 31, 2025 and December 31, 2024, respectively. The Company's investments in equity securities primarily consist of venture investments and employee savings plan related investments. Additionally, the Company's investments included \$3.4 billion and \$3.8 billion of equity method investments primarily in operating businesses in the health care sector as of March 31, 2025 and December 31, 2024, respectively. The allowance for credit losses on held-to-maturity securities at March 31, 2025 and December 31, 2024 was not material.

The amortized cost and fair value of debt securities as of March 31, 2025, by contractual maturity, were as follows:

(in millions)	Available-for-Sale		Held-to-Maturity	
	Amortized Cost	Fair Value	Amortized Cost	Fair Value
Due in one year or less .....	\$ 3,693	\$ 3,670	\$ 341	\$ 341
Due after one year through five years .....	14,251	13,885	120	121
Due after five years through ten years .....	12,248	11,536	14	13
Due after ten years .....	5,291	4,959	17	14
U.S. agency mortgage-backed securities .....	10,410	9,603	—	—
Non-U.S. agency mortgage-backed securities .....	2,939	2,794	—	—
Total debt securities .....	<u>\$ 48,832</u>	<u>\$ 46,447</u>	<u>\$ 492</u>	<u>\$ 489</u>

The fair value of available-for-sale debt securities with gross unrealized losses by major security type and length of time that individual securities have been in a continuous unrealized loss position were as follows:

(in millions)	Less Than 12 Months		12 Months or Greater		Total	
	Fair Value	Gross Unrealized Losses	Fair Value	Gross Unrealized Losses	Fair Value	Gross Unrealized Losses
<b>March 31, 2025</b>						
Debt securities - available-for-sale:						
U.S. government and agency obligations .....	\$ 1,540	\$ (28)	\$ 1,944	\$ (184)	\$ 3,484	\$ (212)
State and municipal obligations .....	2,111	(67)	4,150	(300)	6,261	(367)
Corporate obligations .....	6,855	(146)	10,705	(778)	17,560	(924)
U.S. agency mortgage-backed securities .....	4,032	(114)	4,660	(698)	8,692	(812)
Non-U.S. agency mortgage-backed securities .....	557	(4)	1,745	(144)	2,302	(148)
Total debt securities - available-for-sale .....	<u>\$ 15,095</u>	<u>\$ (359)</u>	<u>\$ 23,204</u>	<u>\$ (2,104)</u>	<u>\$ 38,299</u>	<u>\$ (2,463)</u>
<b>December 31, 2024</b>						
Debt securities - available-for-sale:						
U.S. government and agency obligations .....	\$ 1,475	\$ (51)	\$ 2,152	\$ (223)	\$ 3,627	\$ (274)
State and municipal obligations .....	2,593	(58)	4,085	(317)	6,678	(375)
Corporate obligations .....	7,402	(213)	11,449	(927)	18,851	(1,140)
U.S. agency mortgage-backed securities .....	4,791	(191)	4,674	(803)	9,465	(994)
Non-U.S. agency mortgage-backed securities .....	416	(5)	1,863	(170)	2,279	(175)
Total debt securities - available-for-sale .....	<u>\$ 16,677</u>	<u>\$ (518)</u>	<u>\$ 24,223</u>	<u>\$ (2,440)</u>	<u>\$ 40,900</u>	<u>\$ (2,958)</u>

The Company's unrealized losses from debt securities as of March 31, 2025 were generated from approximately 32,000 positions out of a total of 42,000 positions. The Company believes that it will timely collect the principal and interest due on its debt securities that have an amortized cost in excess of fair value. The unrealized losses were primarily caused by interest rate increases and not by unfavorable changes in the credit quality associated with these securities which impacted the Company's assessment on collectability of principal and interest. At each reporting period, the Company evaluates available-for-sale debt securities for any credit-related impairment when the fair value of the investment is less than its amortized cost. The Company evaluated the expected cash flows, the underlying credit quality and credit ratings of the issuers, noting no significant credit deterioration since purchase. As of March 31, 2025, the Company did not have the intent to sell any of the available-for-sale debt securities in an unrealized loss position. Therefore, the Company believes these losses to be temporary. The allowance for credit losses on available-for-sale debt securities at March 31, 2025 and December 31, 2024 was not material.

### 3. Fair Value

Certain assets and liabilities are measured at fair value in the Condensed Consolidated Financial Statements or have fair values disclosed in the Notes to the Condensed Consolidated Financial Statements. These assets and liabilities are classified into one of three levels of a hierarchy defined by GAAP.

For a description of the methods and assumptions that are used to estimate the fair value and determine the fair value hierarchy classification of each class of financial instrument, see Note 4 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in the 2024 10-K.

The following table presents a summary of fair value measurements by level and carrying values for items measured at fair value on a recurring basis in the Condensed Consolidated Balance Sheets:

(in millions)	Quoted Prices in Active Markets (Level 1)	Other Observable Inputs (Level 2)	Unobservable Inputs (Level 3)	Total Fair and Carrying Value
<b>March 31, 2025</b>				
Cash and cash equivalents .....	\$ 30,183	\$ 534	\$ —	\$ 30,717
Debt securities - available-for-sale:				
U.S. government and agency obligations .....	3,936	129	—	4,065
State and municipal obligations .....	—	6,747	—	6,747
Corporate obligations .....	30	22,730	478	23,238
U.S. agency mortgage-backed securities .....	—	9,603	—	9,603
Non-U.S. agency mortgage-backed securities .....	—	2,794	—	2,794
Total debt securities - available-for-sale .....	3,966	42,003	478	46,447
Equity securities .....	1,708	213	215	2,136
Total assets at fair value .....	<u>\$ 35,857</u>	<u>\$ 42,750</u>	<u>\$ 693</u>	<u>\$ 79,300</u>
Percentage of total assets at fair value .....	<u>45 %</u>	<u>54 %</u>	<u>1 %</u>	<u>100 %</u>
<b>December 31, 2024</b>				
Cash and cash equivalents .....	\$ 25,248	\$ 64	\$ —	\$ 25,312
Debt securities - available-for-sale:				
U.S. government and agency obligations .....	4,194	133	—	4,327
State and municipal obligations .....	—	6,984	—	6,984
Corporate obligations .....	29	22,841	437	23,307
U.S. agency mortgage-backed securities .....	—	9,584	—	9,584
Non-U.S. agency mortgage-backed securities .....	—	2,717	—	2,717
Total debt securities - available-for-sale .....	4,223	42,259	437	46,919
Equity securities .....	1,859	24	65	1,948
Total assets at fair value .....	<u>\$ 31,330</u>	<u>\$ 42,347</u>	<u>\$ 502</u>	<u>\$ 74,179</u>
Percentage of total assets at fair value .....	<u>42 %</u>	<u>57 %</u>	<u>1 %</u>	<u>100 %</u>

There were no transfers in or out of Level 3 financial assets or liabilities during the three months ended March 31, 2025 or 2024.

The following table presents a summary of fair value measurements by level and carrying values for certain financial instruments not measured at fair value on a recurring basis in the Condensed Consolidated Balance Sheets:

(in millions)	Quoted Prices in Active Markets (Level 1)	Other Observable Inputs (Level 2)	Unobservable Inputs (Level 3)	Total Fair Value	Total Carrying Value
<b>March 31, 2025</b>					
Debt securities - held-to-maturity .....	\$ 464	\$ 25	\$ —	\$ 489	\$ 492
Long-term debt and other financing obligations .....	\$ —	\$ 71,337	\$ —	\$ 71,337	\$ 76,036
<b>December 31, 2024</b>					
Debt securities - held-to-maturity .....	\$ 482	\$ 26	\$ —	\$ 508	\$ 512
Long-term debt and other financing obligations .....	\$ —	\$ 70,565	\$ —	\$ 70,565	\$ 75,604

Nonfinancial assets and liabilities or financial assets and liabilities that are measured at fair value on a nonrecurring basis are subject to fair value adjustments only in certain circumstances, such as when the Company records an impairment. The assets and liabilities within our South American operations held for sale as of March 31, 2025 were measured at the lower of carrying value or fair value less cost to sell. Fair value is measured based upon unobservable amounts, such as estimated selling price derived from Company-specific information and market conditions. There were no significant fair value adjustments for assets and liabilities recorded during the three months ended March 31, 2025 or 2024.

#### 4. Medical Costs Payable

The following table shows the components of the change in medical costs payable for the three months ended March 31:

(in millions)	2025	2024
Medical costs payable, beginning of period .....	\$ 34,224	\$ 32,395
Acquisitions (dispositions), net .....	—	(687)
Reported medical costs:		
Current year .....	73,731	66,045
Prior years .....	(320)	(310)
Total reported medical costs .....	73,411	65,735
Medical payments:		
Payments for current year .....	(43,827)	(38,652)
Payments for prior years .....	(26,669)	(24,759)
Total medical payments .....	(70,496)	(63,411)
Less: increase in medical costs payable included within businesses held for sale .....	(3)	—
Medical costs payable, end of period .....	\$ 37,136	\$ 34,032

For the three months ended March 31, 2025 and 2024, prior years' medical cost reserve development included no individual factors that were significant. Medical costs payable included reserves for claims incurred by consumers but not yet reported to the Company of \$25.9 billion and \$23.7 billion at March 31, 2025 and December 31, 2024, respectively.

#### 5. Short-Term Borrowings and Long-Term Debt

As of March 31, 2025, the Company had \$5.2 billion of commercial paper outstanding, with a weighted-average annual interest rate of 4.4%.

For more information on the Company's short-term borrowings, debt covenants and long-term debt, see Note 8 of Notes to the Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in the 2024 10-K.

## **6. Commitments and Contingencies**

### ***Pending Acquisitions***

As of March 31, 2025, the Company had entered into agreements to acquire companies in the health care sector, subject to regulatory approval and other customary closing conditions. The total anticipated capital required for these acquisitions, excluding the payoff of acquired indebtedness, was approximately \$4 billion.

### ***Legal Matters***

The Company is frequently made party to a variety of legal actions and regulatory inquiries, including class actions and suits brought by members, care providers, consumer advocacy organizations, customers and regulators, relating to the Company's businesses, including management and administration of health benefit plans and other services. These matters include medical malpractice, employment, intellectual property, antitrust, privacy and contract claims and claims related to health care benefits coverage and other business practices.

The Company records liabilities for its estimates of probable costs resulting from these matters where appropriate. Estimates of costs resulting from legal and regulatory matters involving the Company are inherently difficult to predict, particularly where the matters: involve indeterminate claims for monetary damages or may involve fines, penalties or punitive damages; present novel legal theories or represent a shift in regulatory policy; involve a large number of claimants or regulatory bodies; are in the early stages of the proceedings; or could result in a change in business practices. Accordingly, the Company is often unable to estimate the losses or ranges of losses for those matters where there is a reasonable possibility or it is probable a loss may be incurred.

### ***Government Investigations, Audits and Reviews***

The Company has been involved or is currently involved in various governmental investigations, audits and reviews. These include routine, regular and special investigations, audits and reviews by the Centers for Medicare and Medicaid Services (CMS), state insurance and health and welfare departments, state attorneys general, the Office of the Inspector General, the Office of Personnel Management, the Office for Civil Rights, the Government Accountability Office, the Federal Trade Commission, U.S. Congressional committees, the U.S. Department of Justice (DOJ), the SEC, the Internal Revenue Service, the U.S. Drug Enforcement Administration, the U.S. Department of Labor, the Federal Deposit Insurance Corporation, the Consumer Financial Protection Bureau, the Defense Contract Audit Agency, the Food and Drug Administration and other governmental authorities. Similarly, the Company's international businesses are also subject to investigations, audits and reviews by applicable foreign governments. The Company has also been responding to subpoenas, information requests and investigations from governmental entities. The Company can provide no assurance as to the scope and outcome of these matters and no assurance as to whether its business, financial condition or results of operations will be materially adversely affected. Certain of the Company's businesses have been reviewed or are currently under review, including for, among other matters, compliance with coding and other requirements under the Medicare risk-adjustment model. CMS has selected certain of the Company's local plans for risk adjustment data validation (RADV) audits to validate the coding practices of and supporting documentation maintained by health care providers and such audits may result in retrospective adjustments to payments made to the Company's health plans.

On February 14, 2017, the DOJ announced its decision to pursue certain claims within a lawsuit initially asserted against the Company and filed under seal by a whistleblower in 2011. The whistleblower's complaint, which was unsealed on February 15, 2017, alleges the Company made improper risk adjustment submissions and violated the False Claims Act. In March 2025, a Special Master appointed by the court issued a report recommending that the court enter summary judgment in the Company's favor on all remaining claims. In April 2025, the DOJ filed a motion asking the court to reject the Special Master's report. The Company cannot reasonably estimate the outcome which may result from this matter given its procedural status.

## 7. Held for Sale

The Company's planned sales of its remaining South American operations are expected to close within the year, subject to regulatory and other customary closing conditions. Assets and liabilities held for sale have been included within prepaid expenses and other current assets and other current liabilities on the Condensed Consolidated Balance Sheet, respectively.

The assets and liabilities of the held for sale disposal groups as of March 31, 2025, were as follows:

(in millions)	Businesses Held for Sale
<b>Assets</b>	
Cash and cash equivalents .....	\$ 310
Accounts receivable and other current assets .....	637
Property, equipment and capitalized software .....	690
Goodwill and other intangible assets .....	440
Other long-term assets .....	287
Remeasurement of assets of businesses held for sale to fair value less cost to sell <sup>(1)</sup> .....	(1,272)
Total assets .....	<u>\$ 1,092</u>
<b>Liabilities</b>	
Medical costs payable .....	\$ 182
Accounts payable and other current liabilities .....	459
Other long-term liabilities .....	411
Total liabilities .....	<u>\$ 1,052</u>

<sup>(1)</sup> Includes the effect of \$849 million of cumulative foreign currency translation losses and \$50 million of noncontrolling interests.

## 8. Segment Financial Information

The Company's four reportable segments are UnitedHealthcare, Optum Health, Optum Insight and Optum Rx. For more information on the Company's segments, see Part I, Item I, "Business" and Note 14 of Notes to the Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in the 2024 10-K.

The following tables present reportable segment financial information:

		Optum						
(in millions)	UnitedHealthcare	Optum Health	Optum Insight	Optum Rx	Optum Eliminations	Optum	Corporate and Eliminations	Consolidated
Three Months Ended March 31, 2025								
Revenues - unaffiliated customers:								
Premiums .....	\$ 81,513	\$ 5,021	\$ —	\$ —	\$ —	\$ 5,021	\$ —	\$ 86,534
Products .....	—	65	44	12,927	—	13,036	—	13,036
Services .....	2,576	3,874	1,501	1,021	—	6,396	—	8,972
Total revenues - unaffiliated customers .....	84,089	8,960	1,545	13,948	—	24,453	—	108,542
Total revenues - affiliated customers .....	—	15,914	3,062	21,137	(1,186)	38,927	(38,927)	—
Investment and other income .....	528	435	23	47	—	505	—	1,033
Total revenues .....	\$ 84,617	\$ 25,309	\$ 4,630	\$ 35,132	\$ (1,186)	\$ 63,885	\$ (38,927)	\$109,575
Total operating costs (a) .....	\$ 79,391	\$ 23,695	\$ 3,669	\$ 33,814	\$ (1,186)	\$ 59,992	\$ (38,927)	\$100,456
Earnings from operations .....	\$ 5,226	\$ 1,614	\$ 961	\$ 1,318	\$ —	\$ 3,893	\$ —	\$ 9,119
Interest expense .....	—	—	—	—	—	—	(998)	(998)
Loss on sale of subsidiary and subsidiaries held for sale .....	(15)	—	—	—	—	—	—	(15)
Earnings before income taxes .....	\$ 5,211	\$ 1,614	\$ 961	\$ 1,318	\$ —	\$ 3,893	\$ (998)	\$ 8,106
Total assets .....	\$ 131,902	\$ 97,722	\$ 34,470	\$ 60,379	\$ —	\$192,571	\$ (14,683)	\$309,790
Purchases of property, equipment and capitalized software .....	196	279	338	85	—	702	—	898
Depreciation and Amortization .....	219	287	344	211	—	842	—	1,061
Three Months Ended March 31, 2024								
Revenues - unaffiliated customers:								
Premiums .....	\$ 72,293	\$ 5,695	\$ —	\$ —	\$ —	\$ 5,695	\$ —	\$ 77,988
Products .....	—	59	41	11,809	—	11,909	—	11,909
Services .....	2,529	3,970	1,702	687	—	6,359	—	8,888
Total revenues - unaffiliated customers .....	74,822	9,724	1,743	12,496	—	23,963	—	98,785
Total revenues - affiliated customers .....	—	16,617	2,731	18,281	(1,016)	36,613	(36,613)	—
Investment and other income .....	535	390	28	58	—	476	—	1,011
Total revenues .....	\$ 75,357	\$ 26,731	\$ 4,502	\$ 30,835	\$ (1,016)	\$ 61,052	\$ (36,613)	\$ 99,796
Total operating costs (a) .....	\$ 70,962	\$ 24,832	\$ 4,012	\$ 29,688	\$ (1,016)	\$ 57,516	\$ (36,613)	\$ 91,865
Earnings from operations .....	\$ 4,395	\$ 1,899	\$ 490	\$ 1,147	\$ —	\$ 3,536	\$ —	\$ 7,931
Interest expense .....	—	—	—	—	—	—	(844)	(844)
Loss on sale of subsidiary and subsidiaries held for sale .....	(7,086)	—	—	—	—	—	—	(7,086)
Earnings before income taxes .....	\$ (2,691)	\$ 1,899	\$ 490	\$ 1,147	\$ —	\$ 3,536	\$ (844)	\$ 1
Total assets .....	\$ 112,840	\$ 94,861	\$ 34,220	\$ 55,291	\$ —	\$184,372	\$ (13,002)	\$284,210
Purchases of property, equipment and capitalized software .....	183	238	245	77	—	560	—	743
Depreciation and Amortization .....	235	272	310	180	—	762	—	997

- (a) Total operating costs include medical costs, operating costs, cost of products sold and depreciation and amortization, as applicable for each reportable segment.

## ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion should be read together with the accompanying Condensed Consolidated Financial Statements and Notes and with our 2024 10-K, including the Consolidated Financial Statements and Notes included in Part II, Item 8, "Financial Statements and Supplementary Data" in that report. Unless the context indicates otherwise, references to the terms "UnitedHealth Group," the "Company," "we," "our" or "us" used throughout this Management's Discussion and Analysis of Financial Condition and Results of Operations refer to UnitedHealth Group Incorporated and its consolidated subsidiaries.

Readers are cautioned that the statements, estimates, projections or outlook contained in this Management's Discussion and Analysis of Financial Condition and Results of Operations, including discussions regarding financial prospects, economic conditions, trends and uncertainties contained in this Item 2, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve risks and uncertainties that may cause our actual results to differ materially from the results discussed or implied in the forward-looking statements. A description of some of the risks and uncertainties is set forth in Part I, Item 1A, "Risk Factors" in our 2024 10-K and in the discussion below.

### **EXECUTIVE OVERVIEW**

#### **General**

UnitedHealth Group is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone. Our two distinct, yet complementary businesses — Optum and UnitedHealthcare — are working to help build a modern, high-performing health system through improved access, affordability, outcomes and experiences for the individuals and organizations we are privileged to serve.

We have four reportable segments:

- Optum Health;
- Optum Insight;
- Optum Rx; and
- UnitedHealthcare, which includes UnitedHealthcare Employer & Individual, UnitedHealthcare Medicare & Retirement and UnitedHealthcare Community & State.

Further information on our business is presented in Part I, Item 1, "Business" and Part II, Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our 2024 10-K and additional information on our segments can be found in this Item 2 and in Note 8 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report.

#### **Business Trends**

Our businesses participate primarily in the United States health markets. We expect overall spending on health care to continue to grow in the future, due to inflation, medical technology and pharmaceutical advancement, regulatory requirements, demographic trends in the population and national interest in health and well-being. The rate of market growth may be affected by a variety of factors, including macroeconomic conditions and regulatory changes, which could impact our results of operations, including our continued efforts to control health care costs.

**Pricing Trends.** To price our health care benefits, products and services, we start with our view of expected future costs, including medical care patterns, the mix and health status of people served, inflation and labor market dynamics. We frequently evaluate and adjust our approach in each of the local markets we serve, considering relevant factors, such as product positioning, price competitiveness and environmental, competitive, legislative and regulatory considerations, including minimum medical loss ratio thresholds and similar revenue adjustments. We will continue seeking to balance growth and profitability across all these dimensions.

The commercial risk market remains highly competitive in the small group, large group and individual segments. We expect broad-based competition to continue as the industry adapts to individual and employer needs.

Medicare Advantage funding continues to be pressured, as discussed below in "Regulatory Trends and Uncertainties" and we have observed increased care patterns as discussed below in "Medical Cost Trends," which may impact pricing and benefit design in future periods.



The Medicaid redetermination process has caused a timing mismatch between the health status of people served through Medicaid and state rate updates. While the updated rates in 2025 more closely align with underlying member acuity, the funding and payment rate environment remains insufficient to meet the health needs of patients and creates the risk of continued downward pressure on Medicaid margin percentages. We continue to take a prudent, market-sustainable posture for both new business and maintenance of existing relationships. We continue to advocate for actuarially sound rates commensurate with our medical cost trends and we remain dedicated to partnering with those states that are committed to the long-term viability of their programs.

**Medical Cost Trends.** Our medical cost trends primarily relate to changes in unit costs, care activity and prescription drug costs. We have observed increased care patterns, more notably related to physician and outpatient care for seniors served through Medicare Advantage, that are above what we expected and contemplated in our benefits design. These elevated care patterns may continue in future periods. Additionally, the Inflation Reduction Act (IRA) altered the Medicare Part D model and benefits, shifting more risk to plans, which results in both increased premiums and medical costs. The IRA also changed the quarterly relationship of medical costs to premiums, altering the seasonal progression and creating a more consistent relationship between medical costs and premiums throughout the year. We endeavor to mitigate medical cost increases by engaging hospitals, physicians and consumers with information and helping them make clinically sound choices, with the objective of helping them achieve high-quality, affordable care.

### **Regulatory Trends and Uncertainties**

**Medicare Advantage Rates.** Medicare Advantage rate notices for numerous years have resulted in industry base rates well below the industry forward medical cost trend, with the Final Notice for 2026 beginning to approach the industry forward medical cost trend. The compounding impact of the previous multi-year rate shortfalls creates sustained pressure on the Medicare Advantage program. Further, substantial revisions to the risk adjustment model, which serves to adjust rates to reflect a patient's health status and care resource needs, have and will result in reduced funding and potentially benefits for people, especially those with some of the greatest health and social challenges.

As a result of ongoing Medicare funding pressures, there are adjustments we can make to partially offset these rate pressures and reductions for a particular period. For example, we can seek to intensify our medical and operating cost management, make changes to the size and composition of our care provider networks, adjust member benefits and implement or increase the member premiums supplementing the monthly payments we receive from the government. Additionally, we decide annually on a county-by-county basis where we will offer Medicare Advantage plans.

### **SELECTED OPERATING PERFORMANCE AND OTHER SIGNIFICANT ITEMS**

The following summarizes select first quarter 2025 year-over-year operating comparisons to first quarter 2024 and other financial results.

- Consolidated revenues grew 10%, UnitedHealthcare revenues grew 12% and Optum revenues grew 5%.
- UnitedHealthcare served 945,000 more people, driven by growth in commercial offerings and Medicare Advantage.
- Consolidated earnings from operations of \$9.1 billion compared to \$7.9 billion last year, with 2024 impacted by the Change Healthcare cyberattack.
- Diluted earnings per common share was \$6.85.
- Cash flows from operations for the three months ended March 31, 2025 were \$5.5 billion.

## RESULTS SUMMARY

The following table summarizes our consolidated results of operations and other financial information:

(in millions, except percentages and per share data)	Three Months Ended March 31,		Increase/ (Decrease)	
	2025	2024	2025 vs. 2024	
Revenues:				
Premiums .....	\$ 86,534	\$ 77,988	\$ 8,546	11 %
Products .....	13,036	11,909	1,127	9
Services .....	8,972	8,888	84	1
Investment and other income .....	1,033	1,011	22	2
Total revenues .....	109,575	99,796	9,779	10
Operating costs:				
Medical costs .....	73,411	65,735	7,676	12
Operating costs .....	13,594	14,077	(483)	(3)
Cost of products sold .....	12,390	11,056	1,334	12
Depreciation and amortization .....	1,061	997	64	6
Total operating costs .....	100,456	91,865	8,591	9
Earnings from operations .....	9,119	7,931	1,188	15
Interest expense .....	(998)	(844)	(154)	18
Loss on sale of subsidiary and subsidiaries held for sale .....	(15)	(7,086)	7,071	nm
Earnings before income taxes .....	8,106	1	8,105	nm
Provision for income taxes .....	(1,632)	(1,222)	(410)	34
Net earnings (loss) .....	6,474	(1,221)	7,695	nm
Earnings attributable to noncontrolling interests .....	(182)	(188)	6	(3)
Net earnings (loss) attributable to UnitedHealth Group common shareholders .....	\$ 6,292	\$ (1,409)	\$ 7,701	nm
Diluted earnings (loss) per share attributable to UnitedHealth Group common shareholders .....	\$ 6.85	\$ (1.53)	\$ 8.38	
Medical care ratio (a) .....	84.8 %	84.3 %	0.5 %	
Operating cost ratio .....	12.4	14.1	(1.7)	
Operating margin .....	8.3	7.9	0.4	
Tax rate .....	20.1	nm	nm	
Net earnings margin (b) .....	5.7	(1.4)	7.1	
Return on equity (c) .....	26.8 %	nm	nm	

nm = not meaningful

(a) Medical care ratio (MCR) is calculated as medical costs divided by premium revenue.

(b) Net earnings margin attributable to UnitedHealth Group shareholders.

(c) Return on equity is calculated as annualized net earnings attributable to UnitedHealth Group common shareholders divided by average shareholders' equity. Average shareholders' equity is calculated using the shareholders' equity balance at the end of the preceding year and the shareholders' equity balances at the end of each of the quarters in the year presented.

## 2025 RESULTS OF OPERATIONS COMPARED TO 2024 RESULTS OF OPERATIONS

### Consolidated Financial Results

#### Revenues

The increases in revenues were primarily driven by growth across our UnitedHealthcare domestic offerings and Optum Rx and pricing trends.

#### Medical Costs and MCR

Medical costs increased primarily due to growth in people served through Medicare Advantage, domestic commercial offerings and those with higher acuity needs; the IRA-driven impacts on Medicare Part D plans and elevated care patterns. The MCR increased as a result of the revenue effects of the Medicare funding reductions, the member profile of newly added patients under value-based care arrangements and elevated care patterns for seniors served through Medicare Advantage, partially offset by the seasonal impacts of the IRA on Medicare Part D and the incremental medical costs for accommodations made to care providers as a results of the Change Healthcare cyberattack incurred in 2024.

## Operating Cost Ratio

The operating cost ratio decreased primarily due to operating cost management; revenue impacts of government programs, including the IRA-driven impacts on Medicare Part D plans; and our direct response efforts to the Change Healthcare cyberattack incurred in 2024, partially offset by investments to support future growth.

## Reportable Segments

See Note 8 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report for more information on our segments. We utilize various metrics to evaluate and manage our reportable segments, including people served by UnitedHealthcare by major market segment and funding arrangement, people served by Optum Health and adjusted scripts for Optum Rx. These metrics are the main drivers of revenue, earnings and cash flows at each business. The metrics also allow management and investors to evaluate and understand business mix, including the level and scope of services provided to people, and pricing trends when comparing the metrics to revenue by segment.

The following table presents a summary of the reportable segment financial information:

(in millions, except percentages)	Three Months Ended March 31,		Increase/ (Decrease)	
	2025	2024	2025 vs. 2024	
<b>Revenues</b>				
UnitedHealthcare .....	\$ 84,617	\$ 75,357	\$ 9,260	12 %
Optum Health .....	25,309	26,731	(1,422)	(5)
Optum Insight .....	4,630	4,502	128	3
Optum Rx .....	35,132	30,835	4,297	14
Optum eliminations .....	(1,186)	(1,016)	(170)	17
Optum .....	63,885	61,052	2,833	5
Eliminations .....	(38,927)	(36,613)	(2,314)	6
Consolidated revenues .....	<u>\$109,575</u>	<u>\$ 99,796</u>	<u>\$ 9,779</u>	10 %
<b>Earnings from operations</b>				
UnitedHealthcare .....	\$ 5,226	\$ 4,395	\$ 831	19 %
Optum Health .....	1,614	1,899	(285)	(15)
Optum Insight .....	961	490	471	96
Optum Rx .....	1,318	1,147	171	15
Optum .....	3,893	3,536	357	10
Consolidated earnings from operations .....	<u>\$ 9,119</u>	<u>\$ 7,931</u>	<u>\$ 1,188</u>	15 %
<b>Operating margin</b>				
UnitedHealthcare .....	6.2 %	5.8 %	0.4 %	
Optum Health .....	6.4	7.1	(0.7)	
Optum Insight .....	20.8	10.9	9.9	
Optum Rx .....	3.8	3.7	0.1	
Optum .....	6.1	5.8	0.3	
Consolidated operating margin .....	8.3 %	7.9 %	0.4 %	

## UnitedHealthcare

The following table summarizes UnitedHealthcare revenues by business:

(in millions, except percentages)	Three Months Ended March 31,		Increase/ (Decrease)	
	2025	2024	2025 vs. 2024	
UnitedHealthcare Employer & Individual - Domestic .....	\$ 19,066	\$ 17,839	\$ 1,227	7 %
UnitedHealthcare Employer & Individual - Global .....	782	1,532	(750)	(49)
UnitedHealthcare Employer & Individual - Total .....	19,848	19,371	477	2
UnitedHealthcare Medicare & Retirement .....	41,705	35,486	6,219	18
UnitedHealthcare Community & State .....	23,064	20,500	2,564	13
Total UnitedHealthcare revenues .....	<u>\$ 84,617</u>	<u>\$ 75,357</u>	<u>\$ 9,260</u>	12 %

The following table summarizes the number of people served by our UnitedHealthcare businesses, by major market segment and funding arrangement:

(in thousands, except percentages)	March 31,		Increase/(Decrease)	
	2025	2024	2025 vs. 2024	
Commercial:				
Risk-based .....	8,410	8,545	(135)	(2)%
Fee-based .....	21,590	20,870	720	3
Total Commercial .....	30,000	29,415	585	2
Medicare Advantage .....	8,245	7,760	485	6
Medicaid .....	7,570	7,680	(110)	(1)
Medicare Supplement (Standardized) .....	4,310	4,325	(15)	—
Total Community and Senior .....	20,125	19,765	360	2
Total UnitedHealthcare - Medical .....	50,125	49,180	945	2
Supplemental Data:				
Medicare Part D stand-alone .....	2,835	3,085	(250)	(8)%
South American businesses held for sale .....	1,160	2,295	(1,135)	(49)%

UnitedHealthcare's revenues increased due to growth in the number of people served through Medicare Advantage, fee-based commercial offerings and those with higher acuity needs and the IRA-driven impacts on Medicare Part D plans, partially offset by decreased people served through risk-based commercial offerings and Medicaid redeterminations throughout 2024. Earnings from operations increased primarily due to growth in people served in Medicare Advantage, the seasonal impact of the IRA on Medicare Part D and the incremental medical costs for accommodations to support care providers as a result of the Change Healthcare cyberattack incurred in 2024, partially offset by the impacts of Medicare Advantage funding reductions and elevated care patterns for seniors served through Medicare Advantage.

### ***Optum***

Total revenues increased primarily due to growth at Optum Rx, partially offset by Optum Health. Earnings from operations increased due to the impacts of the Change Healthcare cyberattack incurred in 2024 and growth at Optum Rx. The results by segment were as follows:

### ***Optum Health***

Revenues at Optum Health decreased primarily due to the conversion of risk-based contracts, Medicare Advantage funding reductions and the profile of members served, partially offset by growth in patients served under value-based arrangements. Earnings from operations decreased due to Medicare Advantage funding reductions, the member profile of newly added patients under value-based care arrangements and elevated care patterns for seniors served through Medicare Advantage, partially offset by cost management initiatives and the incremental medical costs for accommodations to support care providers as a result of the Change Cyberattack incurred in 2024. Optum Health served approximately 99 million people and 104 million people as of March 31, 2025 and March 31, 2024, respectively.

### ***Optum Insight***

Revenues at Optum Insight increased due to decreased business disruption impacts related to the Change Healthcare cyberattack. Earnings from operations at Optum Insight increased due to decreased business disruption impacts and direct response costs related to the Change Healthcare cyberattack.

### ***Optum Rx***

Revenues and earnings from operations at Optum Rx increased due to higher script volumes from both new clients and growth in existing clients and growth in pharmacy services. Earnings from operations also increased due to operating cost efficiencies. Optum Rx fulfilled 408 million and 395 million adjusted scripts in the first quarters of 2025 and 2024, respectively.

## LIQUIDITY, FINANCIAL CONDITION AND CAPITAL RESOURCES

### Liquidity

#### Summary of our Major Sources and Uses of Cash and Cash Equivalents

(in millions)	Three Months Ended March 31,		Increase/ (Decrease)
	2025	2024	2025 vs. 2024
Sources of cash:			
Cash provided by operating activities	\$ 5,456	\$ 1,144	\$ 4,312
Issuances of short-term borrowings and long-term debt, net of repayments	3,911	11,364	(7,453)
Proceeds from common stock issuances	360	486	(126)
Customer funds administered	1,245	1,745	(500)
Sales and maturities of investments, net of purchases	1,217	492	725
Repayments of care provider loans - cyberattack	891	—	891
Total sources of cash	13,080	15,231	(2,151)
Uses of cash:			
Common stock repurchases	(3,000)	(3,072)	72
Cash paid for acquisitions and other transactions, net of cash assumed	(702)	(3,006)	2,304
Purchases of property, equipment and capitalized software	(898)	(743)	(155)
Cash dividends paid	(1,912)	(1,729)	(183)
Loans to care providers - cyberattack	—	(2,164)	2,164
Other	(1,087)	(1,482)	395
Total uses of cash	(7,599)	(12,196)	4,597
Effect of exchange rate changes on cash and cash equivalents	15	(48)	63
Increase in cash and cash equivalents, including cash within businesses held for sale	\$ 5,496	\$ 2,987	\$ 2,509
Less: net increase in cash within businesses held for sale	(91)	—	(91)
Net increase in cash and cash equivalents	\$ 5,405	\$ 2,987	\$ 2,418

#### 2025 Cash Flows Compared to 2024 Cash Flows

Increased cash flows provided by operating activities were driven by changes in working capital accounts, the seasonal impact of the IRA on Medicare Part D and the impacts of the Change Healthcare cyberattack incurred in 2024. Other significant changes in sources or uses of cash year-over-year included net repayments of loans to care providers in response to the Change Healthcare cyberattack, decreased cash paid for acquisitions and increased net sales and maturities of investments, offset by decreased net issuances of short-term borrowings and long-term debt and decreased customer funds administered.

#### Financial Condition

As of March 31, 2025, our cash, cash equivalent, available-for-sale debt securities and marketable equity securities balances of \$79.1 billion included approximately \$30.7 billion of cash and cash equivalents (of which \$1.5 billion was available for general corporate use), \$46.4 billion of debt securities and \$1.9 billion of investments in marketable equity securities. Given the significant portion of our portfolio held in cash and cash equivalents, we do not anticipate fluctuations in the aggregate fair value of our financial assets to have a material impact on our liquidity or capital position. Our available-for-sale debt securities portfolio had a weighted-average duration of 4.2 years and a weighted-average credit rating of “Double A” as of March 31, 2025. When multiple credit ratings are available for an individual security, the average of the available ratings is used to determine the weighted-average credit rating.

#### Capital Resources and Uses of Liquidity

In addition to cash flows from operations and cash and cash equivalent balances available for general corporate use, our capital resources and uses of liquidity are as follows:

**Cash Requirements.** A summary of our cash requirements as of December 31, 2024 was disclosed in Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our 2024 10-K. During the three months ended March 31, 2025, there were no material changes to this previously disclosed information outside the ordinary course of business. We believe our capital resources are sufficient to meet future, short-term and long-term, liquidity needs. We continually evaluate opportunities to expand our operations, including through internal development of new products, programs and technology applications and business combinations.

**Short-Term Borrowings.** Our revolving bank credit facilities provide liquidity support for our commercial paper borrowing program, which facilitates the private placement of unsecured debt through independent broker-dealers, and are available for general corporate purposes. For more information on our commercial paper and bank credit facilities, see Note 5 of the Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report and Note 8 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in our 2024 10-K.

As of March 31, 2025, we were in compliance with the various covenants under our bank credit facilities.

**Long-Term Debt.** Periodically, we access capital markets and issue long-term debt for general corporate purposes, such as to meet our working capital requirements, to refinance debt, to finance acquisitions or for share repurchases. For more information on our long-term debt, see Note 5 of the Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report and Note 8 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in our 2024 10-K.

**Credit Ratings.** Our credit ratings as of March 31, 2025 were as follows:

	Moody's		S&P Global		Fitch		A.M. Best	
	Ratings	Outlook	Ratings	Outlook	Ratings	Outlook	Ratings	Outlook
Senior unsecured debt.....	A2	Stable	A+	Stable	A	Stable	A	Stable
Commercial paper.....	P-1	n/a	A-1	n/a	F1	n/a	AMB-1+	n/a

The availability of financing in the form of debt or equity is influenced by many factors, including our profitability, operating cash flows, debt levels, credit ratings, debt covenants and other contractual restrictions, regulatory requirements and economic and market conditions. A significant downgrade in our credit ratings or adverse conditions in the capital markets may increase the cost of borrowing for us or limit our access to capital.

**Share Repurchase Program.** During the three months ended March 31, 2025, we repurchased approximately 6.0 million shares at an average price of \$503.72 per share. As of March 31, 2025, we had Board of Directors’ authorization to purchase up to 27 million shares of our common stock. The Board of Directors from time to time may further amend the share repurchase program in order to increase the authorized number of shares which may be repurchased under the program.

**Dividends.** Our quarterly cash dividend to shareholders reflects an annual rate of \$8.40.

**Pending Acquisitions.** As of March 31, 2025, we have entered into agreements to acquire companies in the health care sector, subject to regulatory approval and other customary closing conditions. The total anticipated consideration required for these acquisitions, excluding the payoff of acquired indebtedness, was approximately \$4 billion.

For additional liquidity discussion, see Note 10 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in Part II, Item 7 in our 2024 10-K.

## RECENTLY ISSUED ACCOUNTING STANDARDS

There are no recently issued accounting standards that are expected to have a material impact on our Condensed Consolidated Financial Statements.

## CRITICAL ACCOUNTING ESTIMATES

In preparing our Condensed Consolidated Financial Statements, we are required to make judgments, assumptions and estimates, which we believe are reasonable and prudent based on the available facts and circumstances. These judgments, assumptions and estimates affect certain of our revenues and expenses and their related balance sheet accounts and disclosure of our contingent liabilities. We base our assumptions and estimates primarily on historical experience and consider known and projected trends. On an ongoing basis, we re-evaluate our selection of assumptions and the method of calculating our estimates. Actual results, however, may materially differ from our calculated estimates, and this difference would be reported in our current operations.

Our critical accounting estimates include medical costs payable and goodwill. For a detailed description of our critical accounting estimates, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in Part II, Item 7 in our 2024 10-K. For a detailed discussion of our significant accounting policies, see Note 2 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in our 2024 10-K.

## FORWARD-LOOKING STATEMENTS

The statements, estimates, projections, guidance or outlook contained in this document include “forward-looking” statements which are intended to take advantage of the “safe harbor” provisions of the federal securities laws. The words “believe,” “expect,” “intend,” “estimate,” “anticipate,” “forecast,” “outlook,” “plan,” “project,” “should” and similar expressions identify forward-looking statements. These statements may contain information about financial prospects, economic conditions and trends and involve risks and uncertainties. Actual results could differ materially from those that management expects, depending on the outcome of certain factors including: our ability to effectively estimate, price for and manage medical costs; new or changes in existing health care laws or regulations, or their enforcement or application; cyberattacks, other privacy/data security incidents, or our failure to comply with related regulations; reductions in revenue or delays to cash flows received under government programs; changes in Medicare, the CMS star ratings program or the application of risk adjustment data validation audits; the DOJ’s legal action relating to the risk adjustment submission matter; our ability to maintain and achieve improvement in quality scores impacting revenue; failure to maintain effective and efficient information systems or if our technology products do not operate as intended; risks and uncertainties associated with our businesses providing pharmacy care services; competitive pressures, including our ability to maintain or increase our market share; changes in or challenges to our public sector contract awards; failure to achieve targeted operating cost productivity improvements; failure to develop and maintain satisfactory relationships with health care payers, physicians, hospitals and other service providers; the impact of potential changes in tax laws and regulations; increases in costs and other liabilities associated with litigation, government investigations, audits or reviews; failure to complete, manage or integrate strategic transactions; risk and uncertainties associated with the sale of our remaining operations in South America; risks associated with public health crises arising from large-scale medical emergencies, pandemics, natural disasters and other extreme events; failure to attract, develop, retain, and manage the succession of key employees and executives; our investment portfolio performance; impairment of our goodwill and intangible assets; failure to protect proprietary rights to our databases, software and related products; downgrades in our credit ratings; and our ability to obtain sufficient funds from our regulated subsidiaries or from external financings to fund our obligations, reinvest in our business, maintain our debt to total capital ratio at targeted levels, maintain our quarterly dividend payment cycle, or continue repurchasing shares of our common stock.

This above list is not exhaustive. We discuss these matters, and certain risks that may affect our business operations, financial condition and results of operations, more fully in our filings with the SEC, including our reports on Forms 10-K, 10-Q and 8-K. By their nature, forward-looking statements are not guarantees of future performance or results and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify. Actual results may vary materially from expectations expressed or implied in this document or any of our prior communications. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. We do not undertake to update or revise any forward-looking statements, except as required by law.

## ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We manage exposure to market interest rates by diversifying investments across different fixed-income market sectors and debt across maturities, as well as by matching a portion of our floating-rate assets and liabilities, either directly or through the use of interest rate swap contracts. Unrealized gains and losses on investments in available-for-sale debt securities are reported in comprehensive income.

The following table summarizes the impact of hypothetical changes in market interest rates across the entire yield curve by 1% point or 2% points as of March 31, 2025 on our investment income and interest expense per annum, and the fair value of our investments and debt (in millions, except percentages):

Increase (Decrease) in Market Interest Rate	March 31, 2025			
	Investment Income Per Annum	Interest Expense Per Annum	Fair Value of Financial Assets	Fair Value of Financial Liabilities
2 %.....	\$ 777	\$ 645	\$ (4,142)	\$ (8,978)
1 .....	389	322	(2,117)	(4,896)
(1) .....	(389)	(305)	2,169	5,927
(2) .....	(777)	(610)	4,350	13,169

Note: The impact of hypothetical changes in interest rates may not reflect the full 100 or 200 basis point change on interest income and interest expense or on the fair value of financial assets and liabilities as the rates are assumed to not fall below zero.

## ITEM 4. CONTROLS AND PROCEDURES

### ***EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES***

We maintain disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (Exchange Act) that are designed to provide reasonable assurance that information required to be disclosed by us in reports that we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in SEC rules and forms; and (ii) accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

In connection with the filing of this quarterly report on Form 10-Q, management evaluated, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of the design and operation of our disclosure controls and procedures as of March 31, 2025. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of March 31, 2025.

### ***CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING***

There have been no changes in our internal control over financial reporting during the quarter ended March 31, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## PART II. OTHER INFORMATION

### ITEM 1. LEGAL PROCEEDINGS

A description of our legal proceedings is included in and incorporated by reference to Note 6 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report.

### ITEM 1A. RISK FACTORS

In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, Item 1A, “Risk Factors” of our 2024 10-K, which could materially affect our business, financial condition or future results. The risks described in our 2024 10-K are not the only risks facing us. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition or future results.

There have been no material changes to the risk factors as disclosed in our 2024 10-K.

### ITEM 2. UNREGISTERED SALE OF EQUITY SECURITIES AND USE OF PROCEEDS

#### **Issuer Purchases of Equity Securities (a) First Quarter 2025**

<b>For the Month Ended</b>	<b>Total Number of Shares Purchased</b>	<b>Average Price Paid Per Share</b>	<b>Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs</b>	<b>Maximum Number of Shares That May Yet Be Purchased Under The Plans or Programs</b>
	(in millions)		(in millions)	(in millions)
January 31, 2025 .....	2.2	\$ 525.07	2.2	30.9
February 28, 2025 .....	2.9	493.53	2.9	28.0
March 31, 2025 .....	0.9	483.99	0.9	27.1
Total .....	<u>6.0</u>	<u>\$ 503.72</u>	<u>6.0</u>	

- (a) In November 1997, our Board of Directors adopted a share repurchase program, which the Board of Directors evaluates periodically. In June 2024, the Board of Directors amended our share repurchase program to authorize the repurchase of up to 35 million shares of our common stock in open market purchases or other types of transactions (including prepaid or structured repurchase programs), in addition to all remaining shares authorized to be repurchased under the Board’s 2018 renewal of the program. There is no established expiration date for the program. The Board of Directors from time to time may further amend the share repurchase program in order to increase the authorized number of shares which may be repurchased under the program.



## ITEM 5. OTHER INFORMATION

### Trading Arrangements

During the quarter ended March 31, 2025, none of the Company's directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated any contract, instruction or written plan for the purchase or sale of Company securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act or any non-Rule 10b5-1 trading arrangement.

## ITEM 6. EXHIBITS\*

The following exhibits are filed or incorporated by reference herein in response to Item 601 of Regulation S-K. The Company files Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K pursuant to the Securities Exchange Act of 1934 under Commission File No. 1-10864.

- 3.1 Certificate of Incorporation of UnitedHealth Group Incorporated (incorporated by reference to Exhibit 3.1 to the Company's Registration Statement on Form 8-A/A filed on July 1, 2015)
- 3.2 Amended and Restated Bylaws of UnitedHealth Group Incorporated, effective February 23, 2021 (incorporated by reference to Exhibit 3.2 to UnitedHealth Group Incorporated's Current Report on Form 8-K filed on February 26, 2021)
- 4.1 Amended and Restated Indenture, dated as of April 27, 2023, between UnitedHealth Group Incorporated and Wilmington Trust Company, as successor trustee (incorporated by reference to Exhibit 4.1 to UnitedHealth Group Incorporated's Current Report on Form 8-K filed on April 28, 2023)
- 4.2 Indenture, dated as of February 4, 2008, between UnitedHealth Group Incorporated and U.S. Bank National Association (incorporated by reference to Exhibit 4.1 to the Company's Registration Statement on Form S-3, SEC File Number 333-149031, filed on February 4, 2008)
- 4.3 Supplemental Indenture, dated as of April 18, 2023, between UnitedHealth Group Incorporated and U.S. Bank Trust Company, National Association, as trustee, relating to the 6.875% Senior Notes due 2038 (incorporated by reference to Exhibit 4.1 to UnitedHealth Group Incorporated's Current Report on Form 8-K filed on April 24, 2023)
- 31.1 Certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
- 32.1 Certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
- 101.INS XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
- 101.SCH Inline XBRL Taxonomy Extension Schema Document.
- 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document.
- 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document.
- 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document.
- 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document.
- 104 Cover Page Interactive Data File (formatted as Inline XBRL and embedded within Exhibit 101).

---

\* Pursuant to Item 601(b)(4)(iii) of Regulation S-K, copies of instruments defining the rights of certain holders of long-term debt are not filed. The Company will furnish copies thereof to the SEC upon request.

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

UNITEDHEALTH GROUP INCORPORATED

/s/ ANDREW WITTY

**Andrew Witty**

Chief Executive Officer  
(principal executive officer)

Dated: May 6, 2025

/s/ JOHN REX

**John Rex**

President and Chief Financial Officer  
(principal financial officer)

Dated: May 6, 2025

/s/ THOMAS ROOS

**Thomas Roos**

Senior Vice President and  
Chief Accounting Officer  
(principal accounting officer)

Dated: May 6, 2025